Antibody-drug conjugates (ADCs) represent a paradigm shift in oncology, addressing the limitations of conventional chemotherapy by precisely delivering potent cytotoxic agents to tumor cells while minimizing systemic toxicity, thereby enhancing therapeutic efficacy and broadening treatment applications. With 15 FDA-approved ADCs and new drugs like Zynlonta™, Trodelvy®, and Enhertu®, ADCs are revolutionizing targeted cancer treatment. These therapeutics combine antibodies with potent cytotoxic payloads, linked by cleavable or non-cleavable linkers such as protease-sensitive peptides and disulfide-based linkers, which enhance plasma stability while ensuring payload release at tumor sites (Wang).
BroadPharm is your trusted partner in advancing Antibody-Drug Conjugates (ADCs) with our extensive range of hundreds of ADC linkers, including cleavable, non-cleavable, site-specific, and PEG-attached linkers. Our portfolio also features a vast spectrum of conjugatable ADC payloads to meet your research and development needs.
In addition to our premium products, BroadPharm offers specialized, tailored bioconjugation services, including antibody-protein conjugation and ADC development and analysis. Our clinically significant reference ADCs may be employed as controls for comparative ADC studies. Protein A/G drug conjugates, designed to bind IgG antibodies without affecting antigen-binding, use protease-cleavable and non-cleavable linkers, enabling antibody screening to identify the most suitable antibody/linker/drug combinations for your ADC development. Our expertise covers all stages of your ADC development process.
Choose BroadPharm for your bioconjugation technology and service demands, empowering you to bring innovative ADC therapies to life. Our broad portfolio of products accelerates the creation of next-generation targeted cancer therapeutics.
Figure 1: Structure of MC-Val-Cit-PAB-MMAF
Figure 2: Anti-HER2 human monoclonal antibody conjugated with MC-MMAF
Figure 3: Protein A/G Conjugates for Antibody Screening
Figure 4: Bioconjugation Capabilities
As a leading worldwide supplier of bioconjugation products and services, BroadPharm offers an integrative ADC platform with linkers, payloads, references, screening, and ADC conjugation services to empower your advanced research.
Cochran, M., Arias, D., Burke, R., Chu, D., Erdogan, G., Hood, M., ... & Doppalapudi, V. R. (2024). Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-siRNA Conjugates for Drug Development. Journal of medicinal chemistry, 67(17), 14852-14867.
Pistono, P. E., Xu, J., Huang, P., Fetzer, J. L., & Francis, M. B. (2024). Exploring the Effects of Intersubunit Interface Mutations on Virus-Like Particle Structure and Stability. Biochemistry, 63(15), 1913-1924.
Roberts, S. E., Martin, H. L., Al-Qallaf, D., Tang, A. A., Tiede, C., Gaule, T. G., ... & Tomlinson, D. C. (2024). Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles. Iscience, 27(8).
Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: Recent advances in payloads. Acta Pharm Sin B. 2023 Oct;13(10):4025-4059. doi: 10.1016/j.apsb.2023.06.015. Epub 2023 Jun 30. PMID: 37799390; PMCID: PMC10547921.